We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Avenue Therapeutics' Pain Drug Gets Complete Response Letter
Read MoreHide Full Article
Avenue Therapeutics, Inc. (ATXI - Free Report) announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA), through which it is seeking approval for its pipeline candidate intravenous (IV) tramadol. The NDA was filed for the candidate to manage moderate-to-moderately severe post-operative pain in a medically supervised health care setting.
Shares of Avenue Therapeutics plunged almost 59% on Monday following the announcement of the CRL as it may delay tramadol’s approval. The stock has lost 52.8% so far this year compared with the industry’s decline of 4.6%.
The CRL issued by the regulatory authority raised one safety concern. The FDA stated that IV tramadol, which is intended to treat patients in acute pain who require an opioid is not safe for the targeted patient group. The CRL stated that IV tramadol will likely increase the likelihood of opioid-related adverse effects due to possible requirement of two opioid analgesics, one between the first dose of IV tramadol and the onset of analgesia, and another is a rescue analgesic. Moreover, the FDA requested an adequate terminal sterilization validation prior to the NDA approval.
Notably, the NDA for IV tramadol was submitted based on positive data from two pivotal studies evaluating the candidate in patients following bunionectomy and abdominoplasty surgeries.
Data from the studies demonstrated that administration of the candidate achieved a statistically significant improvement in pain intensity as measured by the Sum of Pain Intensity Difference over 48 hours versus placebo. Moreover, data from one study also showed that the candidate has similar efficacy and safety to that of IV morphine, a standard-of-care IV opioid.
The company believes that IV tramadol lessens the potential of abuse and lowers the risk of dependence, and will likely be an effective alternative to intravenous Schedule II conventional opioids. The company is planning to meet the FDA officials to discuss the CRL as soon as possible to resolve the issues. We note that a potential approval will lend a significant boost to the company. There is a great need for safe, effective and non-addictive options that can decrease opioid exposure, given the epidemic of opioid abuse that put companies like J&J (JNJ - Free Report) , Endo International and Mallinckrodt among others under the microscope.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Avenue Therapeutics' Pain Drug Gets Complete Response Letter
Avenue Therapeutics, Inc. (ATXI - Free Report) announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA), through which it is seeking approval for its pipeline candidate intravenous (IV) tramadol. The NDA was filed for the candidate to manage moderate-to-moderately severe post-operative pain in a medically supervised health care setting.
Shares of Avenue Therapeutics plunged almost 59% on Monday following the announcement of the CRL as it may delay tramadol’s approval. The stock has lost 52.8% so far this year compared with the industry’s decline of 4.6%.
The CRL issued by the regulatory authority raised one safety concern. The FDA stated that IV tramadol, which is intended to treat patients in acute pain who require an opioid is not safe for the targeted patient group. The CRL stated that IV tramadol will likely increase the likelihood of opioid-related adverse effects due to possible requirement of two opioid analgesics, one between the first dose of IV tramadol and the onset of analgesia, and another is a rescue analgesic. Moreover, the FDA requested an adequate terminal sterilization validation prior to the NDA approval.
Notably, the NDA for IV tramadol was submitted based on positive data from two pivotal studies evaluating the candidate in patients following bunionectomy and abdominoplasty surgeries.
Data from the studies demonstrated that administration of the candidate achieved a statistically significant improvement in pain intensity as measured by the Sum of Pain Intensity Difference over 48 hours versus placebo. Moreover, data from one study also showed that the candidate has similar efficacy and safety to that of IV morphine, a standard-of-care IV opioid.
The company believes that IV tramadol lessens the potential of abuse and lowers the risk of dependence, and will likely be an effective alternative to intravenous Schedule II conventional opioids. The company is planning to meet the FDA officials to discuss the CRL as soon as possible to resolve the issues. We note that a potential approval will lend a significant boost to the company. There is a great need for safe, effective and non-addictive options that can decrease opioid exposure, given the epidemic of opioid abuse that put companies like J&J (JNJ - Free Report) , Endo International and Mallinckrodt among others under the microscope.
Avenue Therapeutics, Inc. Price
Avenue Therapeutics, Inc. price | Avenue Therapeutics, Inc. Quote
Zacks Rank
Avenue Therapeutics currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>